The relevant experiment has been conducted on mice, so, I don't know how much of its result applies to human beings, but basically what the paper said was that 8 months administration of CLA, at about 2-3% in total calories consumed, caused significant amount of apoptosis of adipocytes. This would be good for bb purposes (if applicable to humans), except that there seemed to be two side effects. (1) development of hyperinsulinemia and (2) enlargement of liver.
As for the development of hyperinsulinemia (insulin insensitivity) caused by CLA administration, in the full article the researchers cite two possible reasons: (1) when blood becomes more full of glucose (from ingested carb, for example), there are not many places for the plasma glucose to go (because fat cells have ... died) and (2) there is market decrease of GLUT4 in adipose tissues. To remove glucose from the blood stream, therefore, it takes lots of insulin.
There is another noteworthy fact from the experiment, and that is CLA caused enlargement of liver. CLA fed mice had liver which were 4 x larger than those mice that were not fed CLA.
QUOTE
However, the liver was massively enlarged and very pale, suggesting deposition of fat (Fig. 1Band C). CLA-fed mice showed 3.6-fold (P < 0.001) and 1.6-fold (NS) enlargement of liver and spleen, respectively.
Histological analysis of liver revealed that there was panlobular macrovesicular steatosis but no increased hepatic inflammation (Fig. 6C). Liver enlargement was manifested 14 days after CLA supplementation (data not shown). No enlargement of the kidney, heart, or skeletal muscles was noted. Despite these marked phenotypic changes,
the average energy intake in the 2 groups was not significantly different (7.4 ± 0.5 and 7.7 ± 0.9 kcal · mouse –1 · day –1 in control and CLA-fed mice, respectively; n = 5).
Histological analysis of liver revealed that there was panlobular macrovesicular steatosis but no increased hepatic inflammation (Fig. 6C). Liver enlargement was manifested 14 days after CLA supplementation (data not shown). No enlargement of the kidney, heart, or skeletal muscles was noted. Despite these marked phenotypic changes,
the average energy intake in the 2 groups was not significantly different (7.4 ± 0.5 and 7.7 ± 0.9 kcal · mouse –1 · day –1 in control and CLA-fed mice, respectively; n = 5).
I am worried about liver enlargement. (1) I don't know if it is applicable to humans (2) I don't know if it is a reversible process (3) and it might be harmful.
From what has been described in the paper, it seems that liver is trying to compensate for the role of dead subcutaneous fat cells. In other words, fat becomes "redistributed"; subcutaneous fat cells die and fat cells in the liver multiply.
=============================================
The abstract of the original paper I am concerned with, is provided below:
"Conjugated linoleic acid supplementation reduces adipose tissue by apoptosis and develops lipodystrophy in mice."
Tsuboyama-Kasaoka N, Takahashi M, Tanemura K, Kim HJ, Tange T, Okuyama H, Kasai M, Ikemoto S, Ezaki O.
Division of Clinical Nutrition, National Institute of Health and Nutrition, Tokyo, Japan.
Conjugated linoleic acid (CLA) is a naturally occurring group of dienoic derivatives of linoleic acid found in beef and dairy products. CLA has been reported to reduce body fat. To examine the mechanism(s) of CLA reduction of fat mass, female C57BL/6J mice were fed standard semipurified diets (10% fat of total energy) with or without CLA (1% wt/wt). Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick endlabeling (TUNEL) and DNA fragmentation analysis revealed that fat-mass decrease by CLA was mainly due to apoptosis. Tumor necrosis factor (TNF)-alpha and uncoupling protein (UCP)-2 mRNA levels increased 12- and 6-fold, respectively, in isolated adipocytes from CLA-fed mice compared with control mice. Because it is known that TNF-alpha induces apoptosis of adipocytes and upregulates UCP2 mRNA, a marked increase of TNF-alpha mRNA with an increase of UCP2 in adipocytes caused CLA-induced apoptosis. However, with a decrease of fat mass, CLA supplementation resulted in a state resembling lipoatrophic diabetes: ablation of brown adipose tissue, a marked reduction of white adipose tissue, marked hepatomegaly, and marked insulin resistance. CLA supplementation decreased blood leptin levels, but continuous leptin infusion reversed hyperinsulinemia, indicating that leptin depletion contributes to the development of insulin resistance. These results demonstrate that intake of CLA reduces adipose tissue by apoptosis and results in lipodystrophy, but hyperinsulinemia by CLA can be normalized by leptin administration.